Page last updated February 4, 2026
Study Design: Intervention Trial
PCORnet Infrastructure: Single IRB, Patient partners or engagement, Clinical Research Collaboration Agreement
Principal Investigator: Daniel Freilich
Institution: Other
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2025
Study Duration: 2026 – 2029
Participating PCORnet® Clinical Research Networks: ADVANCE, GPC, INSIGHT, OneFlorida+, PaTH, REACHnet, STAR
Therapeutic Area: Infectious Disease; Nephrology
Status: Not yet recruiting
Research Question(s): 1) In hospitalized patients with severe infections, does the antibiotic combination workhorse, vancomycin and piperacillin/tazobactam (VPT), cause more kidney injury than another standard antibiotic combination, vancomycin and meropenem (VM), and 2) what is VPT's relative impact on other patient centric outcomes such as mortality, other kidney effects, hospital length of stay, readmissions, complications, and quality of life.